Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.8
USERS' SCORE
Good
Based on 2 Reviews
8.6
Supplement Facts
Serving Size: 1 Chewable Tablet
Amount Per Serving
%DV
Vitamin D3 (as Cholecalciferol) (from Lanolin)
25 mcg (1,000 IU)
125%
Top Medical Research Studies
We explored the effects of vitamin D supplementation in patients with liver cirrhosis—a progressive disease that often manifests alongside vitamin D deficiency. In a carefully designed study, we involved sixty patients who participated in a double-blind, randomized controlled trial. Each patient received either a weekly dose of 50,000 IU of vitamin D or a placebo over 12 weeks.
Throughout the study, we assessed key health markers before and after supplementation, including liver function tests, lipid profiles, and glycaemic indices such as fasting blood glucose and insulin resistance. By the end of the trial, our findings indicated that vitamin D supplementation significantly improved fasting blood glucose levels and insulin resistance in the participants.
Specifically, we observed noteworthy increases in serum 25-hydroxy-vitamin D levels and reductions in fasting blood glucose and insulin resistance indicators. These results suggest that vitamin D might be an important player in improving metabolic health for those suffering from liver cirrhosis.
Throughout the study, we assessed key health markers before and after supplementation, including liver function tests, lipid profiles, and glycaemic indices such as fasting blood glucose and insulin resistance. By the end of the trial, our findings indicated that vitamin D supplementation significantly improved fasting blood glucose levels and insulin resistance in the participants.
Specifically, we observed noteworthy increases in serum 25-hydroxy-vitamin D levels and reductions in fasting blood glucose and insulin resistance indicators. These results suggest that vitamin D might be an important player in improving metabolic health for those suffering from liver cirrhosis.
9
We explored the impact of vitamin D on metabolic associated fatty liver disease (MAFLD) by examining both animal and cell models. Our study involved male C57BL/6J mice, which were put on a high-fat diet and then treated with vitamin D for 16 weeks. At the same time, we analyzed liver cells that were exposed to palmitic acid to mimic fatty liver conditions.
Our findings revealed that vitamin D not only helped reduce body weight and improve liver health, but it also played a role in restoring normal metabolic functions. By reducing inflammation and protecting liver cells from damage, vitamin D enhanced insulin sensitivity and affected fat metabolism positively.
Notably, we found that vitamin D helped inhibit a harmful process known as ferroptosis—a type of cell death linked to liver injury. Through various assays, we confirmed that vitamin D treatment boosted the liver's antioxidant capabilities and lessened iron buildup in liver cells. Overall, our research suggests that vitamin D could be a promising therapeutic option for individuals suffering from MAFLD.
Our findings revealed that vitamin D not only helped reduce body weight and improve liver health, but it also played a role in restoring normal metabolic functions. By reducing inflammation and protecting liver cells from damage, vitamin D enhanced insulin sensitivity and affected fat metabolism positively.
Notably, we found that vitamin D helped inhibit a harmful process known as ferroptosis—a type of cell death linked to liver injury. Through various assays, we confirmed that vitamin D treatment boosted the liver's antioxidant capabilities and lessened iron buildup in liver cells. Overall, our research suggests that vitamin D could be a promising therapeutic option for individuals suffering from MAFLD.
9.5
We designed and synthesized a series of 37 non-steroidal compounds aimed at activating the vitamin D receptor (VDR) to explore their potential in treating liver fibrosis. This condition involves an unhealthy buildup of fibrous tissue in the liver, often leading to serious complications.
Our research found that more than a third of these novel compounds displayed strong affinity for VDR and showed the ability to activate it. Among these, one compound, E15, stood out as particularly effective. It significantly inhibited the activation of hepatic stellate cells (HSCs), which play a critical role in the progression of liver fibrosis, thereby reducing the production of harmful extracellular matrix components.
Encouraged by these promising in vitro results, we proceeded to test E15 in a mouse model of liver fibrosis induced by carbon tetrachloride. The results were remarkable; E15 not only decreased fibrosis and collagen deposition, but also improved liver function without the negative side effect of hypercalcemia, which is often associated with traditional VDR agonists.
These findings suggest that E15 could be a powerful and safer alternative for addressing liver fibrosis, highlighting the significant therapeutic potential of targeting the vitamin D receptor in liver diseases.
Our research found that more than a third of these novel compounds displayed strong affinity for VDR and showed the ability to activate it. Among these, one compound, E15, stood out as particularly effective. It significantly inhibited the activation of hepatic stellate cells (HSCs), which play a critical role in the progression of liver fibrosis, thereby reducing the production of harmful extracellular matrix components.
Encouraged by these promising in vitro results, we proceeded to test E15 in a mouse model of liver fibrosis induced by carbon tetrachloride. The results were remarkable; E15 not only decreased fibrosis and collagen deposition, but also improved liver function without the negative side effect of hypercalcemia, which is often associated with traditional VDR agonists.
These findings suggest that E15 could be a powerful and safer alternative for addressing liver fibrosis, highlighting the significant therapeutic potential of targeting the vitamin D receptor in liver diseases.
Most Useful Reviews
9
Effective vitamin D
13 people found this helpful
While it doesn't taste great, this supplement is effective. My 11-year-old, who has long-standing health issues, experienced improved vitamin D levels from 19 to 106 after six months. He has liver disease and doesn't absorb fat-soluble vitamins well, but this product has not affected his liver parameters. We tried other supplements, but none had such an effect. I continue to use this regularly.
9
Adequate supply
2 people found this helpful
My child has liver disease and requires vitamin D3 for life. This specific supplement is approved because it avoids the fat-soluble form. The jar contains enough tablets for six months at one a day. My child enjoys the small, pleasant-tasting tablets, making it easy to ensure he gets his necessary dose.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 27 Researches
7.8
- All Researches
9.5
We designed and synthesized a series of 37 non-steroidal compounds aimed at activating the vitamin D receptor (VDR) to explore their potential in treating liver fibrosis. This condition involves an unhealthy buildup of fibrous tissue in the liver, often leading to serious complications.
Our research found that more than a third of these novel compounds displayed strong affinity for VDR and showed the ability to activate it. Among these, one compound, E15, stood out as particularly effective. It significantly inhibited the activation of hepatic stellate cells (HSCs), which play a critical role in the progression of liver fibrosis, thereby reducing the production of harmful extracellular matrix components.
Encouraged by these promising in vitro results, we proceeded to test E15 in a mouse model of liver fibrosis induced by carbon tetrachloride. The results were remarkable; E15 not only decreased fibrosis and collagen deposition, but also improved liver function without the negative side effect of hypercalcemia, which is often associated with traditional VDR agonists.
These findings suggest that E15 could be a powerful and safer alternative for addressing liver fibrosis, highlighting the significant therapeutic potential of targeting the vitamin D receptor in liver diseases.
Our research found that more than a third of these novel compounds displayed strong affinity for VDR and showed the ability to activate it. Among these, one compound, E15, stood out as particularly effective. It significantly inhibited the activation of hepatic stellate cells (HSCs), which play a critical role in the progression of liver fibrosis, thereby reducing the production of harmful extracellular matrix components.
Encouraged by these promising in vitro results, we proceeded to test E15 in a mouse model of liver fibrosis induced by carbon tetrachloride. The results were remarkable; E15 not only decreased fibrosis and collagen deposition, but also improved liver function without the negative side effect of hypercalcemia, which is often associated with traditional VDR agonists.
These findings suggest that E15 could be a powerful and safer alternative for addressing liver fibrosis, highlighting the significant therapeutic potential of targeting the vitamin D receptor in liver diseases.
9
We set out to understand how vitamin D might influence liver disease, particularly non-alcoholic fatty liver disease (NAFLD) related to obesity. For our research, we used a high-fat diet to create a mouse model that mimics the condition. We then supplemented these mice with vitamin D via injections over several weeks to see if it could alleviate the liver issues associated with their diet.
Our findings revealed that a high-fat diet led to vitamin D deficiency, insulin resistance, and a notable increase in liver weight. This also resulted in elevated liver enzymes and triglyceride levels, contributing to steatohepatitis, a concerning liver condition. When we introduced vitamin D supplementation, we observed a significant recovery in liver weight and overall improvement in liver health. The treatment also lowered harmful enzymes and triglycerides while helping control markers related to inflammation and fibrosis.
This study highlights that vitamin D supplementation can positively impact liver health in cases linked to obesity, offering an accessible and potentially effective strategy for addressing NAFLD. Notably, we found no adverse effects from the vitamin D treatment, suggesting it could be a safe option for individuals at risk.
Our findings revealed that a high-fat diet led to vitamin D deficiency, insulin resistance, and a notable increase in liver weight. This also resulted in elevated liver enzymes and triglyceride levels, contributing to steatohepatitis, a concerning liver condition. When we introduced vitamin D supplementation, we observed a significant recovery in liver weight and overall improvement in liver health. The treatment also lowered harmful enzymes and triglycerides while helping control markers related to inflammation and fibrosis.
This study highlights that vitamin D supplementation can positively impact liver health in cases linked to obesity, offering an accessible and potentially effective strategy for addressing NAFLD. Notably, we found no adverse effects from the vitamin D treatment, suggesting it could be a safe option for individuals at risk.
We explored the effects of vitamin D supplementation in patients with liver cirrhosis—a progressive disease that often manifests alongside vitamin D deficiency. In a carefully designed study, we involved sixty patients who participated in a double-blind, randomized controlled trial. Each patient received either a weekly dose of 50,000 IU of vitamin D or a placebo over 12 weeks.
Throughout the study, we assessed key health markers before and after supplementation, including liver function tests, lipid profiles, and glycaemic indices such as fasting blood glucose and insulin resistance. By the end of the trial, our findings indicated that vitamin D supplementation significantly improved fasting blood glucose levels and insulin resistance in the participants.
Specifically, we observed noteworthy increases in serum 25-hydroxy-vitamin D levels and reductions in fasting blood glucose and insulin resistance indicators. These results suggest that vitamin D might be an important player in improving metabolic health for those suffering from liver cirrhosis.
Throughout the study, we assessed key health markers before and after supplementation, including liver function tests, lipid profiles, and glycaemic indices such as fasting blood glucose and insulin resistance. By the end of the trial, our findings indicated that vitamin D supplementation significantly improved fasting blood glucose levels and insulin resistance in the participants.
Specifically, we observed noteworthy increases in serum 25-hydroxy-vitamin D levels and reductions in fasting blood glucose and insulin resistance indicators. These results suggest that vitamin D might be an important player in improving metabolic health for those suffering from liver cirrhosis.
9
We explored the relationship between vitamin D and bile duct health, particularly focusing on biliary atresia (BA), a condition that leads to bile duct obstruction in children. Our research centered on vitamin D's receptor (VDR) and its role in protecting bile duct epithelial cells from damage caused by viruses, specifically double-stranded RNA viruses.
Through a combination of laboratory and animal studies, we assessed the expression of VDR in bile duct cells from pediatric patients, noting its connection to cholangitis rates after treatment. We discovered that activating VDR with vitamin D3 significantly reduced cell damage and apoptosis, which is the process of programmed cell death that can worsen BA.
We found that vitamin D3 helped mitigate viral-induced inflammation and cell death through specific cellular pathways, including one called the PLA2/PKC/ERK pathway. This suggests that vitamin D could be a valuable therapeutic option in managing liver diseases like BA, potentially offering new avenues for treatment and patient care.
Through a combination of laboratory and animal studies, we assessed the expression of VDR in bile duct cells from pediatric patients, noting its connection to cholangitis rates after treatment. We discovered that activating VDR with vitamin D3 significantly reduced cell damage and apoptosis, which is the process of programmed cell death that can worsen BA.
We found that vitamin D3 helped mitigate viral-induced inflammation and cell death through specific cellular pathways, including one called the PLA2/PKC/ERK pathway. This suggests that vitamin D could be a valuable therapeutic option in managing liver diseases like BA, potentially offering new avenues for treatment and patient care.
9
We explored the impact of vitamin D on metabolic associated fatty liver disease (MAFLD) by examining both animal and cell models. Our study involved male C57BL/6J mice, which were put on a high-fat diet and then treated with vitamin D for 16 weeks. At the same time, we analyzed liver cells that were exposed to palmitic acid to mimic fatty liver conditions.
Our findings revealed that vitamin D not only helped reduce body weight and improve liver health, but it also played a role in restoring normal metabolic functions. By reducing inflammation and protecting liver cells from damage, vitamin D enhanced insulin sensitivity and affected fat metabolism positively.
Notably, we found that vitamin D helped inhibit a harmful process known as ferroptosis—a type of cell death linked to liver injury. Through various assays, we confirmed that vitamin D treatment boosted the liver's antioxidant capabilities and lessened iron buildup in liver cells. Overall, our research suggests that vitamin D could be a promising therapeutic option for individuals suffering from MAFLD.
Our findings revealed that vitamin D not only helped reduce body weight and improve liver health, but it also played a role in restoring normal metabolic functions. By reducing inflammation and protecting liver cells from damage, vitamin D enhanced insulin sensitivity and affected fat metabolism positively.
Notably, we found that vitamin D helped inhibit a harmful process known as ferroptosis—a type of cell death linked to liver injury. Through various assays, we confirmed that vitamin D treatment boosted the liver's antioxidant capabilities and lessened iron buildup in liver cells. Overall, our research suggests that vitamin D could be a promising therapeutic option for individuals suffering from MAFLD.
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.6
- All Reviews
- Positive Reviews
- Negative Reviews
9
Effective vitamin D
13 people found this helpful
While it doesn't taste great, this supplement is effective. My 11-year-old, who has long-standing health issues, experienced improved vitamin D levels from 19 to 106 after six months. He has liver disease and doesn't absorb fat-soluble vitamins well, but this product has not affected his liver parameters. We tried other supplements, but none had such an effect. I continue to use this regularly.
9
Adequate supply
2 people found this helpful
My child has liver disease and requires vitamin D3 for life. This specific supplement is approved because it avoids the fat-soluble form. The jar contains enough tablets for six months at one a day. My child enjoys the small, pleasant-tasting tablets, making it easy to ensure he gets his necessary dose.
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Chung SI, Liang L, Han H, Park KH, Lee JH, et al. Vitamin D Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obesity Murine Model. Yonsei Med J. 2025;66:75. doi:10.3349/ymj.2024.0038
- Derogar Kasmaei SR, Parastouei K, Hosseini Ahangar B, Saberifiroozi M, Taghdir M. Effects of vitamin D supplementation on the glycaemic indices, lipid profile and liver function tests in patients with cirrhosis: a double-blind randomised controlled trial. BMJ Nutr Prev Health. 2024;7:e000938. doi:10.1136/bmjnph-2024-000938
- Liu N, Zhao P, Cao P, Hui J, Pan Y, et al. Vitamin D3/VDR alleviates double-stranded RNA virus -induced biliary epithelial cell damage by inhibiting autophagy. BMC Gastroenterol. 2025;25:44. doi:10.1186/s12876-025-03640-5
- Zou C, Liu X, He M, Sun Y, Sang Y, et al. Insulin Resistance Mediates the Association Between Vitamin D and Non-Alcoholic Fatty Liver Disease. Int J Prev Med. 2024;15:77. doi:10.4103/ijpvm.ijpvm_221_23
- Diaz-Ruiz R, Poca M, Roman E, Panadero-Gomez R, Cuyàs B, et al. Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis. Nutrients. 2025;17. doi:10.3390/nu17020226
- Wang Y, Jin J, Chen S, Shen Y. Modulation of magnesium intake on the association between vitamin D deficiency and severe hepatic steatosis in overweight and obese individuals. Magnes Res. 2024;37:58. doi:10.1684/mrh.2024.0536
- Jiang R, Lu M, Hua Y, Hong Z. Association between serum vitamin D and depression among non-alcoholic fatty liver disease. Asia Pac J Clin Nutr. 2025;34:112. doi:10.6133/apjcn.202502_34(1).0011
- Gao F, Guan C, Cheng N, Liu Y, Wu Y, et al. Design, synthesis, and anti-liver fibrosis activity of novel non-steroidal vitamin D receptor agonists based on open-ring steroid scaffold. Eur J Med Chem. 2025;286:117250. doi:10.1016/j.ejmech.2025.117250
- Biswas SA, Rukunuzzaman M, Biswas RK, Rahman SMH, Alam MS. Serum Vitamin D Status in Infants with Cholestatic Jaundice. Mymensingh Med J. 2025;34:192.
- Munoli AS, Mantur PG, Jalawadi VM. Child-Pugh Score and Vitamin D: Exploring a New Frontier in Liver Cirrhosis Assessment. Cureus. 2024;16:e74738. doi:10.7759/cureus.74738
- Liang Y, Jiang X, Zhao X, Tang T, Fan X, et al. Vitamin D alleviates HFD-induced hepatic fibrosis by inhibiting DNMT1 to affect the TGFβ1/Smad3 pathway. iScience. 2024;27:111262. doi:10.1016/j.isci.2024.111262
- Miao Y, Jiang Z, Song H, Zhang Y, Chen H, et al. Vitamin D supplementation alleviates high fat diet-induced metabolic associated fatty liver disease by inhibiting ferroptosis pathway. Eur J Nutr. 2024;64:50. doi:10.1007/s00394-024-03554-0
- Huang N, Su X, Yu T, Wu X, Lu B, et al. Serum 25-hydroxy vitamin D level is associated with elastography-detected liver fibrosis in patients with type 2 diabetes mellitus in China. Front Endocrinol (Lausanne). 2024;15:1420088. doi:10.3389/fendo.2024.1420088
- Johnson CD, Stevens CM, Bennett MR, Litch AB, Rodrigue EM, et al. The Role of Vitamin D Deficiency in Hepatic Encephalopathy: A Review of Pathophysiology, Clinical Outcomes, and Therapeutic Potential. Nutrients. 2024;16. doi:10.3390/nu16234007
- Morsy MA, Abdel-Latif R, Ibrahim MF, Marey H, Abdel-Gaber SA. Calcitriol ameliorates cisplatin-induced hepatorenal toxicity via regulation of Nrf2-Mrp2/p38 MAPK signaling in mice. Int J Immunopathol Pharmacol. 2024;38:3946320241306276. doi:10.1177/03946320241306276
- Luo WJ, Dong XW, Ye H, Zhao QS, Zhang QB, et al. Vitamin D 1,25-Dihydroxyvitamin D reduces lipid accumulation in hepatocytes by inhibiting M1 macrophage polarization. World J Gastrointest Oncol. 2024;16:4685. doi:10.4251/wjgo.v16.i12.4685
- Kilani Y, Alsakarneh S, Madi MY, Mosquera DAG, Ferreira MN, et al. Autoimmune Hepatitis and Vitamin D Deficiency: A Nationwide Perspective. Aliment Pharmacol Ther. 2025;61:682. doi:10.1111/apt.18438
- Dai J, Song J, Chen X, Ding F, Ding Y, et al. 1,25(OH)D-treated mouse bone marrow-derived dendritic cells alleviate autoimmune hepatitis in mice by improving TFR/TFH imbalance. Immunopharmacol Immunotoxicol. 2025;47:59. doi:10.1080/08923973.2024.2435314
- Yaribeygi H, Ramezani M, Katsiki N, Mirmohammadkhani M, Tabaei NS. Efficacy of Adding Sitagliptin to Ongoing Metformin on Metabolic Profile, Triglyceride-Glucose Index, Vitamin D3, and Liver Tests in Patients Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. Curr Ther Res Clin Exp. 2024;101:100764. doi:10.1016/j.curtheres.2024.100764
- Farrash WF, Idris S, Elzubier ME, Khidir EBA, Aslam A, et al. Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction-associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways. Int J Exp Pathol. 2024;105:219. doi:10.1111/iep.12519
- Dharshan SS, Ramamurthy K, Kaliraj S, Manikandan K, Chitra V, et al. Combined effects of vitamin D3 and dioxopiperidinamide derivative on lipid homeostasis, inflammatory pathways, and redox imbalance in non-alcoholic fatty liver disease in vivo zebrafish model. Biotechnol Appl Biochem. 2024. doi:10.1002/bab.2666
- Fogacci F, Giovannini M, Di Micoli V, Grandi E, Borghi C, et al. Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Nutrients. 2024;16. doi:10.3390/nu16152454
- Abdel-Hamid GR, Mostafa DM, Fathy RM, Lotfy DM, Osman S. Cytokine storm modulation using cholecalciferol and low dose gamma radiation in Escherichia coli infected mice. Cell Biochem Funct. 2024;42:e4026. doi:10.1002/cbf.4026
- Yang A, Chen Y, Gao Y, Lv Q, Li Y, et al. Vitamin D exacerbates steatosis while calcipotriol inhibits inflammation in non-alcoholic fatty liver disease in knockout mice: a comparative study of two forms of vitamin D. Food Funct. 2024;15:4614. doi:10.1039/d4fo00215f
- Lu Y, Chen H, Chen Y, Zhao L, Hou S. Accumulated LPS induced by colitis altered the activities of vitamin D-metabolizing hydroxylases and decreased the generation of 25-hydroxyvitamin D. Chem Biol Interact. 2024;395:110997. doi:10.1016/j.cbi.2024.110997
- Lee SB, Jin MH, Yoon JH. The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunction. Sci Rep. 2024;14:6714. doi:10.1038/s41598-024-57380-9
- Guo E, Yuan H, Li R, Yang J, Liu S, et al. Calcitriol ameliorates the progression of hepatic fibrosis through autophagy-related gene 16-like 1-mediated autophagy. Am J Med Sci. 2024;367:382. doi:10.1016/j.amjms.2024.02.010
